OL-101 / Overland Therapeutics - LARVOL DELTA

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study (ASH 2025) - P1 | "We report preliminary data from an ongoing phase I, first-in-human, dose-escalation and dose-expansion study (NCT06644118). Patients with R/R MM who had received ≥3 prior lines of therapies underwent standardlymphodepletion (fludarabine/cyclophosphamide) followed by a single OL-101 infusion at 3 dose levels(DL1: 1.0×106, DL2: 2.0×106, DL3: 1.5×106 cells/kg)...At the 2.0×106 cells/kg dose level, 1 of 6 patientsexperienced a DLT, manifested as grade 4 CRS with onset on Day 3 post-infusion, which resolved by Day17 following treatment with tocilizumab, steroids, plasma exchange and other supportive care... OL-101, a novel bispecific BCMA/GPRC5D VHH CAR-T, demonstrates promising efficacy (100%ORR, 100% MRD negativity) and manageable safety (CRS manageable, no ICANS) in heavily pretreated,triple-class exposed R/R MM patients, with no new safety signals identified than those with previouslyreported BCMA or GPRC5D targeting CAR-T cells. Notably,..."

IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia • GPRC5D

OL-101, A BCMA/GPRC5D DUAL-TARGETING CAR-T, INDUCES DEEP RESPONSES IN HEAVILY PRETREATED ADVANCED MYELOMA, PARTICULARLY IN PATIENTS POST BCMA- OR GPRC5D-TARGETED THERAPY OR WITH EXTRAMEDULLARY DISEASE (EHA 2026) - P1 | "Summary/Conclusion OL-101 demonstrates a manageable safety profile and highly compelling preliminary efficacy in heavily pretreated, high-risk R/R MM populations. The achievement of universal, deep MRD ‑ negative responses in patients with prior BCMA ‑ or GPRC5D ‑ directed therapy and in those with EMD supports dual ‑ targeting CAR ‑ T strategies to overcome antigen escape and therapeutic resistance."

CAR T-Cell Therapy • Clinical • IO biomarker • Metastases • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia • GPRC5D • TNFRSF17

Molecular epidemiology of antimicrobial resistance and virulence of carbapenem-resistant Klebsiella pneumoniae in South China. (PubMed, Front Microbiol) - "The main Sequence Type (ST) type, capsular serotype, and LPS serotype among CRKP isolates in South China were ST11, KL47, and OL101, respectively...In South China, highly virulent and MDR CRKP strains show a trend toward epidemic, underscoring the urgent need for ongoing genomic surveillance and stringent infection control measures. KPC-2 variant KPC-12 and ST413-1LV-KL112 hvCRKP, a novel type of hvCRKP carrying bla NDM-1, require particular attention and further investigation."

Journal • Infectious Disease • Pneumonia

OL101 - Vestibular Crash Course (separate ticket required) (AAA 2026) - "• Upon completion, participants will be able to integrate clinical data to determine appropriate diagnostic and management strategies. • Upon completion, participants will be able to describe abnormal findings for vestibular diagnostic testing."

Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae. (PubMed, Microbiol Res) - "The outbreak was sustained by ST11-KL47-OL101 KPC-2-NDM-5-CRKPs, which exhibited non-susceptible to all antimicrobials available in mainland China...Phylogenetic evaluation was carried out with a total of 327 KPC-NDM-CRKP genomes to provide a global perspective on such strains, and potential transmission events in other global regions were also observed during the COVID-19 period. The outbreak of such strains in the real world and the co-transfer of blaKPC and blaNDM would exacerbate the dispersal of KPC-NDM-CRKPs, which poses a severe threat to public health."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia

Clinical and genomic characterization of Klebsiella pneumoniae infections in Dhaka, Bangladesh. (PubMed, J Glob Antimicrob Resist) - "Our findings suggest alarming levels of AMR among Kpn isolates in Bangladesh and a critical need for improved treatment modalities and vaccine development."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • Septic Shock

Genomics of Klebsiella pneumoniae and Escherichia coli in pediatric infectious diseases in Pakistan (ASTMH 2024) - "40 distinct K-loci were identified, of which predominant K-loci included KL81 (n=13, 12.6%) & KL64 (n=11, 10.6%); 10 distinct O-loci were identified, predominant O-loci included O1/O2v2 (n=29, 28.1%), O1/02v1 (n=25, 24.2%), & OL101 (n=18, 15.3%)... This study underscores need for vaccines targeting Klebsiella pneumoniae and Escherichia coli , significant contributors to neonatal sepsis and MDR. Genome sequencing can help identify patterns related to virulence and factors that contribute to immunity or successful vaccine response"

Clinical • Late-breaking abstract • Infectious Disease • Pediatrics • Pneumonia • Septic Shock